An expanded-access trial of Trappsol Cyclo (Hydroxypropyl-betadex) in patients with Niemann-Pick Disease Type C

Trial Profile

An expanded-access trial of Trappsol Cyclo (Hydroxypropyl-betadex) in patients with Niemann-Pick Disease Type C

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Hydroxypropyl betadex (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 Results (n=11) published in a CTD Holdings media release.
    • 16 Feb 2017 According to a CTD Holdings media release, updated data from the study were presented in a poster presentation at the 13th Annual WORLDSymposium.
    • 10 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top